It's been one week since Wanda Lee-Ballou received University of Virginia (UVA) Health's first dose of Ocravus Zunovo – the ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...

She started treatment with etanercept (Enbrel ®) 1 month previously. One day after a subcutaneous injection into the left thigh, she developed a mildly pruritic eruption on the right thigh ...

Transenteric delivery via the RaniPill yielded 80% relative bioavailability versus SC and differences between PK parameters ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with ...

US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...

that can be given by monthly subcutaneous injection in the EU. The green light means that anti-complement C5 antibody PiaSky (crovalimab) has now been cleared in the top four world pharma markets ...

Vyalev is the first and only FDA-approved subcutaneous 24-hour infusion of a levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson disease.

Dianthus Therapeutics' DNTH103 is in phase 2 trials for gMG, CIDP, and MMN, offering a differentiated, convenient dosing ...

Novo Nordisk’s Alhemo® (concizumab) has been recommended for approval by the European Medicines Agency's (EMA) Committee for ...